Phio Pharmaceuticals Corp. current report, 13 November 2014

Full document

Business Context and Reporting Period

Company: RXi Pharmaceuticals Corporation (Note: Metadata lists "Phio Pharmaceuticals Corp.", but the filing identifies the registrant as RXi Pharmaceuticals Corporation).

Filing Type: Form 8-K (Current Report).

Report Date: November 13, 2014.

Reporting Period: The filing announces results of operations for the quarter ended September 30, 2014.

Key Financial Metrics

The provided text is a cover sheet for the Form 8-K and does not contain specific financial data.

  • Revenue: Not provided in the filing text.
  • Profit/Loss: Not provided in the filing text.
  • Cash Flow: Not provided in the filing text.
  • Margins: Not provided in the filing text.
  • Debt and Liquidity: Not provided in the filing text.

Note: The filing states that detailed results are contained in a press release furnished as Exhibit 99.1, which is not included in the input text.

Material Changes

The filing text does not provide specific numerical comparisons or material changes versus the prior comparable period. It only confirms the reporting of results for the quarter ended September 30, 2014.

Guidance, Outlook, and Risks

Management Commentary: The filing references a press release (Exhibit 99.1) for the full details of the results but does not include the commentary itself.

Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not treated as "filed" under Section 18 of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated.

Risks and Contingencies: No specific risks or contingencies are detailed in the provided text.

Investor Verification Checklist

  • Verify the actual financial figures (revenue, net loss, cash position) by reviewing the attached Press Release (Exhibit 99.1), as they are absent from the 8-K cover sheet.
  • Confirm the company name discrepancy between the metadata ("Phio Pharmaceuticals Corp.") and the filing ("RXi Pharmaceuticals Corporation").
  • Check for any forward-looking statements or guidance in the full press release that may not be captured in this summary.